JPS6121529B2 - - Google Patents
Info
- Publication number
- JPS6121529B2 JPS6121529B2 JP14163379A JP14163379A JPS6121529B2 JP S6121529 B2 JPS6121529 B2 JP S6121529B2 JP 14163379 A JP14163379 A JP 14163379A JP 14163379 A JP14163379 A JP 14163379A JP S6121529 B2 JPS6121529 B2 JP S6121529B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- acetylsalicylate
- acetylsalicylic acid
- injection
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 18
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 16
- 229940068372 acetyl salicylate Drugs 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 13
- 238000002347 injection Methods 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 9
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 8
- 239000001110 calcium chloride Substances 0.000 claims description 8
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 8
- 229960002449 glycine Drugs 0.000 claims description 7
- 235000013905 glycine and its sodium salt Nutrition 0.000 claims description 7
- 239000003381 stabilizer Substances 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- JJBCTCGUOQYZHK-UHFFFAOYSA-N 2-acetyloxybenzoate;(5-amino-1-carboxypentyl)azanium Chemical compound OC(=O)C(N)CCCC[NH3+].CC(=O)OC1=CC=CC=C1C([O-])=O JJBCTCGUOQYZHK-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 238000004040 coloring Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- -1 amino acid salt Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- GICLSALZHXCILJ-UHFFFAOYSA-N ctk5a5089 Chemical compound NCC(O)=O.NCC(O)=O GICLSALZHXCILJ-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14163379A JPS5665816A (en) | 1979-11-01 | 1979-11-01 | Acetylsalicylate pharmaceutical for injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14163379A JPS5665816A (en) | 1979-11-01 | 1979-11-01 | Acetylsalicylate pharmaceutical for injection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5665816A JPS5665816A (en) | 1981-06-03 |
| JPS6121529B2 true JPS6121529B2 (de) | 1986-05-27 |
Family
ID=15296572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP14163379A Granted JPS5665816A (en) | 1979-11-01 | 1979-11-01 | Acetylsalicylate pharmaceutical for injection |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5665816A (de) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01112835U (de) * | 1988-01-26 | 1989-07-28 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63307824A (ja) * | 1987-06-09 | 1988-12-15 | Teisan Seiyaku Kk | 安定化注射用粉末製剤 |
| US7230014B1 (en) | 1997-10-14 | 2007-06-12 | Eisai Co., Ltd. | Pharmaceutical formulation comprising glycine as a stabilizer |
| ATE332133T1 (de) * | 1997-10-14 | 2006-07-15 | Eisai Co Ltd | Pharmazeutische zusammensetzung enthaltend glyzin als stabilisator |
| DE102005025283A1 (de) | 2005-06-02 | 2006-12-07 | Bayer Healthcare Ag | Stabiler Wirkstoffkomplex von Salzen der o-Acetylsalicylsäure mit basischen Aminosäuren und Glycin |
| JP2008114896A (ja) * | 2006-11-07 | 2008-05-22 | Kyocera Mita Corp | 梱包製品の取り出し補助板 |
-
1979
- 1979-11-01 JP JP14163379A patent/JPS5665816A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01112835U (de) * | 1988-01-26 | 1989-07-28 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5665816A (en) | 1981-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS5838421B2 (ja) | 分岐鎖状ケト酸のオルニチン及びアルギニン塩並びに肝臓及び腎臓障害の治療への使用 | |
| US4942166A (en) | Crystalline purine compounds | |
| US4285964A (en) | Salts of (+)-catechine, their preparation and use, and compositions containing these salts | |
| CA1040532A (en) | Process for producing solid bismuth-containing pharmaceutical compositions | |
| JPS6121528B2 (de) | ||
| PT1609481E (pt) | Composições farmacêuticas injectáveis compreendendo diclofenaco de sódio de beta-ciclodextrina e um polissorbato | |
| PT95564B (pt) | Processo para a preparacao de (+)-ibuprofen-d-aminoacido uteis como analgesicos intensificados de ataque acelerado | |
| TWI279230B (en) | Pregabalin composition | |
| KR20140123081A (ko) | 아미노산과 카르복실산을 포함한 게르마늄의 착체 및 이를 제조하는 방법 | |
| JPS6121529B2 (de) | ||
| JPS5828862B2 (ja) | ベンザルコニウムクロソドのヨウ素化誘導体、その製造法および該誘導体を有効成分とする殺菌剤 | |
| JPH07503941A (ja) | スパルフロキサシンの溶液、その調製及びそれから成る塩 | |
| CN103301101B (zh) | 2-(2-氟-4-联苯基)-丙酸的新型药物组合物 | |
| US2697059A (en) | Hydroxy aromatic carboxylate-resin adsorption composition | |
| KR100251395B1 (ko) | 피소스티그민 유도체와 이의 용도 및 이를 함유한 제약적 조제물 | |
| US3002886A (en) | Betaine salicylates and the method for their preparation | |
| HU226686B1 (en) | Semisolid pharmaceutical formulation containing dexketoprofen trometamol | |
| KR830000525B1 (ko) | 주사용 아세틸 살리실레이트 분말제의 안정화 방법 | |
| PT92142B (pt) | Processo para a preparacao de solucoes parentericas estaveis contendo 2-fenil- -1,2-benzisoselenazol-3 (h)-ona | |
| US3362879A (en) | Tyrosine tranquilizing compositions and methods of treatment | |
| US3755592A (en) | Method of preparing high concentration calcium ascorbate reaction products and products produced by same | |
| DE354848T1 (de) | Pharmazeutische und/oder diaetetische zusammensetzungen mit gehalt an l-carnitin und l-lysin. | |
| JPS6119632B2 (de) | ||
| JPS6021147B2 (ja) | ピロリドンカルボン酸クレアチニン | |
| RU2238086C2 (ru) | Новая лекарственная форма n-(4-нитро-2-феноксифенил) метансульфонамида, способ ее получения и применения |